Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: SmithKline Beecham

This article was originally published in The Tan Sheet

Executive Summary

SmithKline Beecham: "Don't expect us to make another big acquisition tomorrow," SB Chairman and CEO Jan Leschly told Alex. Brown May 17, as the company must make the necessary synergies with its 1994 buying spree. Last year, SmithKline acquired pharmacy benefit management firm DPS in May for $2.3 bil., bought Sterling Health for $2.9 bil. in August and divested Sterling Health North America in September for $1 bil. ("The Tan Sheet" Sept. 19, 1994, pp. 1-4). In November, SB sold its animal health business to Pfizer for $1.45 bil. SmithKline will continue investing in numerous small company collaborative ventures, Leschly noted. SmithKline has made 130 deals in the last three years with small or start-up companies, he noted...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS083841

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel